Beta Bionics, Inc. (NASDAQ:BBNX) Stock Has Average Price Target of $21.90

Beta Bionics, Inc. (NASDAQ:BBNX) has been given an average rating of “Moderate Buy” by the thirteen brokerages that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and eight have given a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $22.91.

Several research analysts have recently weighed in on BBNX shares. William Blair began coverage on shares of Beta Bionics in a report on Friday, August 21st. They set a “market perform” rating for the company. The Goldman Sachs Group raised their target price on shares of Beta Bionics from $17.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Leerink Partners lifted their target price on shares of Beta Bionics from $24.00 to $27.00 and gave the stock an “outperform” rating in a research report on Monday, September 14th. Robert W. Baird boosted their target price on shares of Beta Bionics from $14.00 to $16.00 and gave the company a “neutral” rating in a research note on Tuesday, September 15th. Finally, Wall Street Zen raised Beta Bionics from a “sell” rating to a “hold” rating in a report on Saturday, September 19th.

Beta Bionics Stock Performance

NASDAQ BBNX opened at $21.76 on Tuesday. Beta Bionics has a one year low of $8.80 and a one year high of $32.71. The stock has a 50-day moving average of $18.08 and a 200 day moving average of $14.37. The company has a market capitalization of $978.98 million, a price-to-earnings ratio of -13.19 and a beta of 3.37.

Beta Bionics (NASDAQ:BBNX) last posted its earnings results on Wednesday, July 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.09. The business had revenue of $32.01 million for the quarter. Beta Bionics had a negative net margin of 61.31% and a negative return on equity of 26.30%. On average, equities analysts predict that Beta Bionics will post -2.06 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Beta Bionics news, insider Mike Mensinger sold 2,650 shares of the firm’s stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $22.00, for a total value of $58,300.00. Following the transaction, the insider directly owned 177,390 shares of the company’s stock, valued at approximately $3,902,580. This trade represents a 1.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Stephen Feider sold 6,675 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $19.11, for a total value of $127,559.25. Following the completion of the transaction, the chief financial officer directly owned 159,378 shares in the company, valued at $3,045,713.58. The trade was a 4.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 102,223 shares of company stock valued at $1,983,398 over the last ninety days. 5.30% of the stock is owned by insiders.

Hedge Funds Weigh In On Beta Bionics

Several institutional investors and hedge funds have recently bought and sold shares of BBNX. Caitong International Asset Management Co. Ltd grew its holdings in Beta Bionics by 1,075.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock valued at $61,000 after purchasing an additional 1,818 shares during the period. Legal & General Group Plc bought a new position in shares of Beta Bionics in the second quarter worth about $62,000. The Manufacturers Life Insurance Company bought a new position in shares of Beta Bionics in the second quarter worth about $172,000. ProShare Advisors LLC purchased a new position in shares of Beta Bionics during the 4th quarter valued at about $217,000. Finally, Ieq Capital LLC purchased a new position in shares of Beta Bionics during the 2nd quarter valued at about $229,000.

Key Stories Impacting Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Wells Fargo initiated coverage of Beta Bionics with an “overweight” rating and a $28 price target. Truist Financial also raised its target from $23 to $28 and maintained a “buy” rating, implying potential upside from the recently reported trading level. Analyst coverage and price targets
• Neutral Sentiment: Several law firms—including Robbins LLP, Faruqi & Faruqi, Rosen Law Firm, Pomerantz, Kaplan Fox and others—publicized the same securities class action and reminded investors of the November 3, 2026 deadline to seek lead-plaintiff status. The repeated notices do not represent new allegations, but they increase attention around the litigation. Faruqi securities class action deadline notice
• Negative Sentiment: The lawsuit alleges that Beta Bionics failed to disclose or adequately describe FDA concerns, including a June 2025 Form 483 and more than 18,000 complaints involving the iLet insulin-delivery system. The allegations are unproven, but potential regulatory, reputational and legal costs are weighing on investor sentiment. Johnson Fistel Beta Bionics investor alert
• Negative Sentiment: Director Christy Jones sold 6,430 shares for approximately $147,890, reducing her position by about 24.7%. The transaction was executed under a pre-arranged Rule 10b5-1 plan, which makes it a weaker discretionary bearish signal, but it nevertheless adds to reported insider-selling activity. SEC Form 4 insider-sale filing

About Beta Bionics

Beta Bionics, Inc is a medical technology company focused on developing automated insulin-delivery systems for people with diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to simplify diabetes management by using continuous glucose monitoring data to adjust insulin dosing with limited user input.

The iLet Bionic Pancreas received clearance from the U.S. Food and Drug Administration in 2023 for use by people with type 1 diabetes.